At a glance
- GHRP-6 is not an FDA-approved drug: Drugs@FDA has no record of it.
- FDA lists it in Category 2, bulk substances that may present significant safety risks in compounding (since September 29, 2023).
- PubMed lists 639 publications mentioning it, including 19 randomized controlled trials and 351 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
FDA's stated risk · Original FDA text (English) Compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity. Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.
- Ghrelin Receptor Blockade Restricts Hepatic Echinococcus granulosus Infection by Suppressing Host Cell Proliferation and Enhancing Fibrotic Encapsulation.
- Ghrelin attenuates hypoxia-induced mitochondrial oxidative stress damage in HTR-8/SVneo trophoblasts.
- Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.
- Ghrelin impairs embryo development after ovarian hyperstimulation.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
- The Ghrelin/GHSR-1a Axis Attenuates Preeclampsia-like Features with Decidual Macrophage Reprogramming and Improved Placental Remodeling.
- Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
- Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.
- Oral salmon acylated ghrelin increases food intake in common carp (Cyprinus carpio) via ghrelin receptors, likely through sensory nerves rather than systemic absorption.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.